Drug Profile
Research programme: abuse-resistant analgesics - Acura Pharmaceuticals
Alternative Names: acetaminophen/niacin/oxycodone; acetaminophen/oxycodone; acetaminophen/oxycodone/niacin; Acuracet; Acuracet with Niacin; niacin/acetaminophen/oxycodone; niacin/oxycodone/acetaminophen; niacin/oxycodone/paracetamol; niacin/paracetamol/oxycodone; oxycodone/acetaminophen; oxycodone/acetaminophen/niacin; oxycodone/niacin/acetaminophen; oxycodone/niacin/paracetamol; oxycodone/paracetamol; oxycodone/paracetamol/niacin; paracetamol/niacin/oxycodone; paracetamol/oxycodone; paracetamol/oxycodone/niacinLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Acura Pharmaceuticals
- Class Acetanilides; Morphine derivatives; Small molecules
- Mechanism of Action Opioid receptor agonists; Prostaglandin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA (PO, Immediate release)
- 26 Sep 2012 Acura Pharmaceuticals announced a letter agreement with Pfizer providing for the termination of Pfizer's license to Acura's AVERSION Technology used in three developmental opioid products as of 26 September 2012 and the transfer of those products, one of which is oxycodone/paracetamol and another undisclosed opioid, back to Acura. This represents an earlier return of development products to Acura
- 26 Jul 2012 Pfizer exercises its right to terminate its licence for oxycodone/paracetamol and another undisclosed opioid in Canada, Mexico, USA